Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | FLT3 D586_D593delinsGG |
Gene Variant Detail | |
Relevant Treatment Approaches |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
FLT3 D586_D593delinsGG | hematologic cancer | predicted - sensitive | Quizartinib | Preclinical - Biochemical | Actionable | In a preclinical study, Vanflyta (quizartinib) inhibited Flt3 phosphorylation in cells expressing FLT3 D586_D593delinsGG in culture (PMID: 37246158). | 37246158 | |
FLT3 D586_D593delinsGG | hematologic cancer | predicted - sensitive | Sorafenib | Preclinical - Biochemical | Actionable | In a preclinical study, Nexavar (sorafenib) inhibited Flt3 phosphorylation in cells expressing FLT3 D586_D593delinsGG in culture (PMID: 37246158). | 37246158 |